Table 1 Demographic and clinical characteristics of colorectal cancer cases according to PD-L1+ and PD-L1 macrophage densities.

From: Spatially resolved multimarker evaluation of CD274 (PD-L1)/PDCD1 (PD-1) immune checkpoint expression and macrophage polarisation in colorectal cancer

Characteristic

Total N

Overall cell density (cells/mm2)

Median (25–75th percentiles)

PD-L1+ macrophages

P

PD-L1 macrophages

P

All cases

910 (100%)

59 (16–170)

 

560 (380–780)

 

Sex

  

0.50

 

0.47

  Male

464 (51%)

60 (17–160)

 

570 (390–790)

 

  Female

446 (49%)

59 (15–190)

 

560 (370–770)

 

Age (years)

  

0.18

 

0.95

  <65

247 (27%)

54 (15–160)

 

580 (360–790)

 

  65–75

331 (36%)

58 (15–150)

 

560 (390–750)

 

  >75

332 (36%)

74 (18–230)

 

550 (370–800)

 

Tumour location

  

0.0012

 

0.19

  Proximal colon

445 (49%)

74 (20–220)

 

580 (420–790)

 

  Distal colon

332 (36%)

51 (12–140)

 

530 (360–750)

 

  Rectum

133 (15%)

38 (15–160)

 

560 (360–750)

 

AJCC stage

  

<0.0001

 

0.0049

  I

151 (17%)

84 (19–210)

 

500 (340–670)

 

  II

342 (38%)

84 (26–210)

 

540 (390–790)

 

  III

301 (33%)

47 (11–130)

 

590 (420–800)

 

  IV

116 (13%)

26 (6.6–100)

 

650 (370–890)

 

Tumour grade

  

<0.0001

 

0.73

  Low-grade (well to moderately differentiated)

760 (84%)

55 (15–160)

 

560 (370–780)

 

  High-grade (poorly differentiated)

150 (16%)

104 (24–310)

 

570 (410–760)

 

Lymphovascular invasion

  

<0.0001

 

0.20

  No

719 (79%)

70 (21–190)

 

550 (380–770)

 

  Yes

191 (21%)

32 (6.5–100)

 

600 (380–820)

 

MMR status

  

<0.0001

 

0.20

  MMR proficient

772 (85%)

48 (12–150)

 

550 (370–780)

 

  MMR deficient

137 (15%)

190 (60–350)

 

590 (460–770)

 

BRAF status

  

<0.0001

 

0.046

  Wild-type

763 (84%)

52 (14–160)

 

550 (370–770)

 

  Mutant

147 (16%)

98 (37–290)

 

590 (440–790)

 
  1. AJCC American Joint Committee on Cancer, MMR mismatch repair.